NASDAQ · NAOV
Healthcare · Medical - Devices
$1.90
Up+$0.02 (+1.06%)
Updated Aug 14, 2026, 7:07 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NAOV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NAOV.
NAOV research
Company profile and research snapshot.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
defenseworld.net · Dec 2, 2025
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings and
businesswire.com · Nov 19, 2025
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today issued a letter to shareholders, highlighting the Company's strategic vision, market opportunities and a rebranding initiative. Dear Shareholders, Since assuming the role of CEO in June 2025, our team has completed a comprehensive review of our operations, technologies and market opportunities. Throughout this pr.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NAOV.
No results
No recent SID articles mention NAOV.
